ArticleEFSA journal. European Food Safety Authority2026
Assessment of fall-back MRLs for revoked CXLs previously implemented in the EU legislation.
Article in EFSA journal. European Food Safety Authority, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the 56th meeting of the Codex Committee on Pesticide Residues (CCPR meeting) held in September 2025 and the subsequent 48th meeting of the Codex Alimentarius Commission (CAC) (November 2025), 352 Codex MRLs (CXLs) for 30 active substances (a.s.) were revoked. In accordance with Article 43 of Regulation (EC) 396/2005, EFSA was requested by the European Commission to identify the revoked CXLs which had been previously taken over in the EU MRL legislation (Regulation (EC) No 396/2005) and, if possible, propose fall-back Maximum Residue Levels (MRLs) to replace the revoked CXLs. Based on the detailed assessment and taking into account the information provided by Member States, EFSA proposed fall-back MRLs for chlormequat, fenpyroximate and flubendiamide. For parathion-methyl, methamidophos, methoprene and cyproconazole, EFSA proposed to lower all the existing MRLs under assessment to the limit of quantification (LOQ). For spinosad, EFSA proposed to postpone the assessment of the fall-back MRLs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.